We are excited to announce the addition of five anti–folate-binding protein (FBP) monoclonal antibodies (MAbs) (Cat. # 4FBP3) to our Blood Coagulation and Anemia portfolio. 

Anemia is a major global public health challenge, affecting an estimated 40% of children, 37% of pregnant women, and 30% of women worldwide (WHO). Because anemia has multiple causes, diagnostic workups often include evaluation of treatable nutritional deficiencies, including folate (vitamin B9) deficiency. Folate deficiency is a well-known cause of megaloblastic anemia, particularly in pregnancy, making folate testing an important tool in anemia evaluation and prenatal care. 

Most immunochemical folate assays measure folate with a competitive format, where labelled folate competes with endogenous folate for binding to FBP. This folate-FBP complex is commonly immobilized via an anti-FBP antibody. For reliable measurement, Hytest’s anti-FBP MAbs are designed to: 

✔ Specifically binding to FBP 

✔ Not interfere with the binding sites for folate/folic acid 

Furthermore, assay cross-reactivity with folate-like substances can compromise folate determination. During the in-house testing, Hytest MAbs showed no cross-reactivity with methotrexate or phenytoin and very low cross-reactivity with aminopterin, supporting accurate measurement of natural folate in human serum samples. 

For details, please contact Hytest NA Sales team or access the # 4FBP3 product page.